# Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Study · id `cardio:ct-nct03087773` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03087773](<https://clinicaltrials.gov/study/NCT03087773>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03087773

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.

## Technical summary

Registry record NCT03087773. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-11 (actual); primary completion 2022-05-03 (actual). Results posted on 2024-08-22.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 476 participants (enrolled count; ClinicalTrials.gov record NCT03087773, source copy `cardio:ctgov-nct03087773-2024-08-22`, retrieved 2026-10-26)
- Started: 2017-05-11 (actual) (ClinicalTrials.gov record NCT03087773, source copy `cardio:ctgov-nct03087773-2024-08-22`, retrieved 2026-10-26)
- Primary completion: 2022-05-03 (actual) (ClinicalTrials.gov record NCT03087773, source copy `cardio:ctgov-nct03087773-2024-08-22`, retrieved 2026-10-26)
- Completion: 2022-05-17 (actual) (ClinicalTrials.gov record NCT03087773, source copy `cardio:ctgov-nct03087773-2024-08-22`, retrieved 2026-10-26)
- Results first posted: 2024-08-22 (ClinicalTrials.gov record NCT03087773, source copy `cardio:ctgov-nct03087773-2024-08-22`, retrieved 2026-10-26)
- Countries: Austria (ClinicalTrials.gov record NCT03087773, source copy `cardio:ctgov-nct03087773-2024-08-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03087773-2024-08-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
- Acronym: EMMY
- Condition: Acute Myocardial Infarction
- Intervention (Drug): Empagliflozin 10 mg
- Intervention (Drug): Placebo Oral Tablet
- Lead sponsor: Medical University of Graz
- Lead sponsor class: OTHER
- Collaborator: United Arab Emirates University
- Collaborator class: OTHER
- Collaborator: Medical University of Vienna
- Collaborator class: OTHER
- Collaborator: Landeskrankenhaus Feldkirch
- Collaborator class: OTHER
- Collaborator: Paracelsus Medical University
- Collaborator class: OTHER
- Collaborator: Hospital Rudolfstiftung
- Collaborator class: OTHER
- Collaborator: Klinikum Klagenfurt am Wörthersee
- Collaborator class: OTHER
- Collaborator: Barmherzige Brüder Eisenstadt
- Collaborator class: OTHER
- Collaborator: Cardinal Schwarzenberg Hospital
- Collaborator class: OTHER
- Collaborator: Johannes Kepler University of Linz
- Collaborator class: OTHER
- Collaborator: Landesklinikum Sankt Polten
- Collaborator class: OTHER
- Collaborator: Landeskrankenhaus II Graz West
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Medical University of Graz (`cardio:org-medical-university-of-graz`)
- Registry lists this organization as a collaborator: Medical University of Vienna (`cardio:org-medical-university-of-vienna`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Empagliflozin in acute myocardial infarction: the EMMY trial (`cardio:pubmed-36036746`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial (`cardio:pubmed-37407956`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial (`cardio:pubmed-37236318`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial (`cardio:pubmed-39297940`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b6729edc81c1bc42e9a073966b62a96166b6d90ad28657189e8cecc81f87a204
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
